Our results showed that SLC19A3 mRNA level was significantly decreased in 12 of 15 (80%) breast cancer tumor tissues when compared to their adjacent non-tumor breast tissues (fold change ranging from −2 to −50, P<0.005; Wilcoxon paired test; Figure 1). This evidence concerns the gene SLC19A3 and neoplasm.